05-12-2025  10:15 am   •   PDX and SEA Weather

  • 1
  • 2
  • 3
  • 4

NORTHWEST NEWS

Senator-designate Courtney Neron to Serve Remainder of Term Held by Late Senator Aaron Woods

County commissioners in Washington, Clackamas and Yamhill counties have chosen State Rep. Courtney Neron yesterday to serve in Senate Dist.13. The district covers Wilsonville, Sherwood, King City, Tigard and parts of Beaverton and Yamhill County. It was most recently represented by the late Sen. Aaron Woods

Bill to Help Churches, Nonprofits Turn Extra Property into Affordable Housing Advances to Senate

Faith leaders estimate there are thousands of acres of prime real estate being offered by shrinking congregations. 

Food For All Oregonians Bill Moves Forward For Young Children

SB 611 would extend food benefits to all eligible young children, regardless of immigration status.

Albina Vision Trust, No More Freeways Clash During City Council Hearing

No More Freeways claims ODOT is planning larger expansion than expected.

NEWS BRIEFS

East Portland TIF District Community Leadership Committees – Applications Now Open

Each district-specific committee’s purpose is to advise PHB and Prosper Portland staff, the Portland City Council, and the Prosper...

Merkley, Wyden Blast Trump Administration’s Attacks on Head Start

42 lawmakers write to RFK Jr. demanding answers on Trump admin’s actions undermining Head Start as Trump reportedly plans to...

Alerting People About Rights Is Protected Under Oregon Senate Bill

Senate Bill 1191 says telling someone about their rights isn’t a crime in Oregon. ...

1803 Fund Makes Investment in Black Youth Education

The1803 Fund has announced a decade-long investment into Self Enhancement Inc. and Albina Head Start. The investment will take shape...

Senate Democrats Keep School Book Decisions Local and Fair

The Freedom to Read bill says books depicting race, sex, religion and other groups have to be judged by the same standards as all...

OPINION

Cuts to Minority Business Development Agency Leaves 3 Staff

6B CDFI affordable capital for local investment also at risk ...

The Courage of Rep. Al Green: A Mandate for the People, Not the Powerful

If his colleagues truly believed in the cause, they would have risen in protest beside him, marched out of that chamber arm in arm with him, and defended him from censure rather than allowing Republicans to frame the narrative. ...

Bending the Arc: Advancing Equity in a New Federal Landscape

January 20th, 2025 represented the clearest distillation of the crossroads our country faces. ...

Trump’s America Last Agenda is a Knife in the Back of Working People

Donald Trump’s playbook has always been to campaign like a populist and govern like an oligarch. But it is still shocking just how brutally he went after our country’s working people in the first few days – even the first few hours – after he was...

AFRICAN AMERICANS IN THE NEWS

ENTERTAINMENT

U.S. & WORLD NEWS

By The Skanner News | The Skanner News

WASHINGTON (AP) — Federal health experts said Wednesday the much-debated diabetes pill Avandia increases the risk of heart attack compared to other diabetes drugs.
A majority of 33 expert panelists said the former blockbuster drug is riskier than older diabetes medicines, including its closest competitor.
The Food and Drug Administration has convened the panel to help untangle reams of conflicting data over whether the GlaxoSmithKline drug increases heart risks.
The panel is considering a series of questions culminating with a vote on whether Avandia should be withdrawn from the market.
The FDA is not required to follow the group's advice, though it often does. A final decision will be made in coming months.
Avandia has been under federal scrutiny since 2007, when an analysis first suggested it might cause heart attack.
The FDA has been down this road before. Three years ago a similar FDA panel voted to keep Avandia on the market and the FDA responded by adding bolder warning labels to the drug.
"In terms of what has changed since 2007, I think the totality of evidence is much stronger," said panelist Clifford Rosen of the Maine Medical Research Institute. "It's still not absolute but it's stronger. Clearly there is a signal."
The panel voted 21-4 that Avandia is more likely to cause heart attack than its closest competitor Actos. Eight panelists said there was not enough information to make a decision.
"While I'm not persuaded by the evidence to implicate the drug, I'm also not reassured by the evidence to exonerate it," said Dr. Sanjay Kaul of Cedars-Sinai Medical Center in Los Angeles.
The FDA first approved Avandia in 1999 and it quickly became the top-selling diabetes pill in the world. U.S. sales have plummeted from $2.2 billion in 2006 to $520 million last year as safety concerns swirled around the drug.
Since diabetics are already predisposed to heart risks it is extremely difficult to tell which heart attacks are drug-related and which are simply a result of the underlying disease.
The task of evaluating the possible side effects has dragged on for years without definitive answers.